Flezurafenib
Flezurafenib is an investigational new drug that is being evaluated by Jazz Pharmaceuticals for the treatment of cancers that are driven by oncogenic mutations that activate the RAS-RAF-MAPK signaling pathway.
≈ 1 min read
Flezurafenib. encyclopegia.org, snapshot enwiki-001362705054. /a/flezurafenib
Names in other languages
No names in other languages are held for this entry yet.
Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.
Flezurafenib is an investigational new drug that is being evaluated by Jazz Pharmaceuticals for the treatment of cancers that are driven by oncogenic mutations that activate the RAS-RAF-MAPK signaling pathway. It acts as a rapidly accelerated fibrosarcoma (RAF) kinase inhibitor. As of January 2025, flezurafenib has reached Phase 1 clinical trials, where it is being evaluated for the treatment of advanced solid tumors.
Text derived from https://en.wikipedia.org/w/index.php?oldid=1362705054 under CC BY-SA 4.0; modifications have been made.